Story outline
- According to 2020 data, 5 million people in the United States have Alzheimer’s disease.
- Researchers are working to understand the various risk factors that may contribute to the development of the disease.
- Researchers investigated the role of newly identified microproteins in neuronal mitochondria.
A new study reveals the possible role of certain proteins in the development of Alzheimer’s disease, a disease that affects five million people in the United States. Estimate From 2020.
In a study published today, molecular psychiatry, researchers have identified a new gene in mitochondrial DNA that encodes a ‘microprotein’ named SHMOOSE. They analyzed default and mutated versions of this small protein and found that mutated versions were associated with increased risk of Alzheimer’s disease, brain atrophy, and alterations in energy metabolism.
The recent discovery of SHMOOSE has caused some to question its effectiveness. Amyloid research Or plaques that form in the brain.
The team believes that SHMOOSE, found in the mitochondria of neurons, is important for energy signaling and metabolism in the central nervous system. Microprotein levels found in cerebrospinal fluid correlated with other markers of Alzheimer’s disease.
In experiments, they administered SHMOOSE directly into the brain of rats and found evidence that the protein is active in the brain. Hypothalamus, the part of the brain that produces hormones for body temperature, heart rate and hunger. Further laboratory experiments using cultured cells confirmed that unmutated forms of microproteins can affect mitochondrial metabolism.
“This discovery opens exciting new directions for developing precision medicine-based therapies for Alzheimer’s disease, with a focus on SHMOOSE as a target area,” said Professor of Gerontology, Medicine and Biological Sciences. Yes, says Pinchas Cohen, senior author of the study. press release“Administration of SHMOOSE analogues to individuals who carry the mutation and produce the mutant protein may prove beneficial in neurodegenerative and other aging diseases.”
